Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay

Journal of Clinical Virology

Volumn 69, Issue , 2015, Pages 150-155

  Fischer, Lena ^a   Sampaio, Kerstin Laib ^b   Jahn, Gerhard ^a   Hamprecht, Klaus ^a   Göhring, Katharina ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antiviral resistance; Cidofovir; Cytomegalovirus; Foscarnet; Ganciclovir; Stem cell transplantation

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; CYTOSINE; DNA DIRECTED DNA POLYMERASE; GANCICLOVIR KINASE; PHOSPHONIC ACID DERIVATIVE; PHOSPHOTRANSFERASE; UL54 PROTEIN, HUMAN HERPESVIRUS 5; VIRUS PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CASE REPORT; CHILD; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; FEMALE; FIBROBLAST; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; INFANT; LIVER TRANSPLANTATION; MALE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SCHOOL CHILD; TAY SACHS DISEASE; UL54 GENE; UL97 GENE; VIROGENESIS; VIRUS ENCEPHALITIS; VIRUS GENE; VIRUS PNEUMONIA; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; MULTIDRUG RESISTANCE; MUTATION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CELL LINE; CHILD; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GANCICLOVIR; GENOTYPE; HUMANS; INFANT; MALE; MUTATION; ORGANOPHOSPHONATES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); VIRAL PROTEINS;

EID: 84937948059     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.06.090     Document Type: Article

References (33)

1. Boutolleau D., Deback C., Bressollette-Bodin C., Conan F., Aït-Arkoub Z., Imbert-Marcille B.M., Agut H. Genetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factor. Antivir. Ther. 2009, 14:847-852.
2. Chevillotte M., Schubert A., Mertens T., von Einem J. Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 2009, 53:3752-3761.
3. Chou S., Erice A., Jordan M.C., Vercellotti G.M., Michels K.R., Talarico C.L., Stanat S.C., Biron K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 1995, 171:576-583.
4. Chou S., Guentzel S., Michels K.R., Miner R.C., Drew W.L. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 1995, 172:239-242.
5. Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., Miner R.C., Drew W.L. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 1997, 176:786-789.
6. Chou S., Lurain N.S., Weinberg A., Cai G.Y., Sharma P.L., Crumpacker C.S. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob. Agents Chemother. 1999, 43:1500-1502.
7. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., Drew W.L. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 2002, 185:162-169.
8. Chou S., Lurain N.S., Thompson K.D., Miner R.C., Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 2003, 188:32-39.
9. Chou S., Van Wechsel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance muations by using recombinant virus incorporating a reporter gene. Antimicrob. Agents Chemother. 2005, 49:2710-2715.
10. Chou S., Marousek G., Li S., Weinberg A. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J. Clin. Virol. 2008, 43:107-109.
11. Cihlar T., Fuller M.D., Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 1998, 72:5927-5936.
12. Drouot E., Piret J., Boivin G. Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J. Clin. Microbiol. 2013, 51:3216-3224.
13. Eckle T., Prix L., Jahn G., Klingebiel T., Handgretinger R., Selle B., Hamprecht K. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000, 96:3286-3289.
14. Emery V.C., Griffinth P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8039-8044.
15. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 1999, 12:286-297.
16. Fischer L., Laib Sampaio K., Jahn G., Hamprecht K., Göhring K. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. Antiviral Res. 2013, 100:575-577.
17. Göhring K., Wolf D., Bethge W., Mikeler E., Faul C., Vogel W., Vöhringer M.C., Jahn G., Hamprecht K. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J. Clin. Virol. 2013, 57:43-49.
18. Laib Sampaio K., Jahn G., Sinzger C. Virus-host interactions: methods and protocols. Methods Mol. Bio. 2013, 1064. 10.1007/978-1-62703-601-6_14.
19. Liu W., Shum C., Martin D.F., Kuppermann B.D., Hall A.J., Margolis T.P. Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis. J. Infect. Dis. 2000, 182:1234-1238.
20. Lurain N.S., Weinberg A., Crumpacker C.S., Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 2001, 45:2775-2780.
21. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010, 23:689-721.
22. Mahy B.W.J., Kangro H.O. Virology Methods Manual 1996, Academic Press, San Diego, California.
23. Martin M., Azzi A., Lin S.X., Boivin G. Opposite effects of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. Antivir. Ther. 2010, 15:579-586.
24. Pichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., Parker B.O., Pari G.S. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 1999, 73:5663-5670.
25. Prix L., Maierl J., Jahn G., Hamprecht K. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J. Clin. Virol. 1998, 11:29-37.
26. Scott G.M., Weinberg A., Rawlinson W.D., Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 2007, 51:89-94.
27. Shi R., Azzi A., Gilbert C., Boivin G., Lin S.X. Three-dimensional modelling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006, 64:301-307.
28. Sinzger C. Entry route of HCMV into endothelial cells. J. Clin. Virol. 2007, 41:174-179.
29. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 1997, 176:69-77.
30. Tischer B.K., von Einem J., Kaufer B., Osterrieder N. Two-step mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 2006, 40:191-197.
31. Tischer B.K., Smith G.A., Osterrieder N. En passant mutagenesis: a two stepp markerless recombination system. Methods Mol. Bio 2010, 634:421-430.
32. Wang D., Yu Q., Schröer J., Shenk T. Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc. Natl. Acad. Sci. 2007, 104(50):20037-20042.
33. Wolf D., Smith I.L., Lee D.J., Freeman W.R., Flores-Aguilar M., Spector S. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Invest. 1995, 95:257-263.